DOCU Quote, Financials, Valuation and Earnings

Box has a net margin of 8.27% compared to DocuSign's net margin of 4.67%. DocuSign's return on equity of 70.42% beat Box's return on equity of 429.55%.

DocuSign has a consensus price target of --, signalling upside risk potential of 1.13%. On the other hand Box has an analysts' consensus of $36.89 which suggests that it could grow by 15.21%. Given that Box has higher upside potential than DocuSign, analysts believe Box is more attractive than DocuSign.

DocuSign has a beta of 0.920, which suggesting that the stock is 8.009% less volatile than S&P 500. In comparison Box has a beta of 0.859, suggesting its less volatile than the S&P 500 by 14.051%.

DocuSign has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Box offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DocuSign pays -- of its earnings as a dividend. Box pays out 11.58% of its earnings as a dividend. Box's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

DocuSign quarterly revenues are $754.8M, which are larger than Box quarterly revenues of $275.9M. DocuSign's net income of $62.4M is higher than Box's net income of $12.9M. Notably, DocuSign's price-to-earnings ratio is 19.56x while Box's PE ratio is 40.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DocuSign is 6.82x versus 4.40x for Box. Usually stocks with elevated PS ratios are considered overvalued.

Salesforce has a net margin of 8.27% compared to DocuSign's net margin of 16.17%. DocuSign's return on equity of 70.42% beat Salesforce's return on equity of 10.11%.

DocuSign has a consensus price target of --, signalling upside risk potential of 1.13%. On the other hand Salesforce has an analysts' consensus of $394.98 which suggests that it could grow by 14.9%. Given that Salesforce has higher upside potential than DocuSign, analysts believe Salesforce is more attractive than DocuSign.

DocuSign has a beta of 0.920, which suggesting that the stock is 8.009% less volatile than S&P 500. In comparison Salesforce has a beta of 1.304, suggesting its more volatile than the S&P 500 by 30.388%.

DocuSign has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Salesforce offers a yield of 0.47% to investors and pays a quarterly dividend of $0.40 per share. DocuSign pays -- of its earnings as a dividend. Salesforce pays out -- of its earnings as a dividend.

DocuSign quarterly revenues are $754.8M, which are smaller than Salesforce quarterly revenues of $9.4B. DocuSign's net income of $62.4M is lower than Salesforce's net income of $1.5B. Notably, DocuSign's price-to-earnings ratio is 19.56x while Salesforce's PE ratio is 56.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DocuSign is 6.82x versus 9.04x for Salesforce. Usually stocks with elevated PS ratios are considered overvalued.

Datadog has a net margin of 8.27% compared to DocuSign's net margin of 7.49%. DocuSign's return on equity of 70.42% beat Datadog's return on equity of 8.68%.

DocuSign has a consensus price target of --, signalling upside risk potential of 1.13%. On the other hand Datadog has an analysts' consensus of $159.88 which suggests that it could grow by 7.74%. Given that Datadog has higher upside potential than DocuSign, analysts believe Datadog is more attractive than DocuSign.

DocuSign has a beta of 0.920, which suggesting that the stock is 8.009% less volatile than S&P 500. In comparison Datadog has a beta of 1.114, suggesting its more volatile than the S&P 500 by 11.381%.

DocuSign has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Datadog offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DocuSign pays -- of its earnings as a dividend. Datadog pays out -- of its earnings as a dividend.

DocuSign quarterly revenues are $754.8M, which are larger than Datadog quarterly revenues of $690M. DocuSign's net income of $62.4M is higher than Datadog's net income of $51.7M. Notably, DocuSign's price-to-earnings ratio is 19.56x while Datadog's PE ratio is 280.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DocuSign is 6.82x versus 22.01x for Datadog. Usually stocks with elevated PS ratios are considered overvalued.

Synopsys has a net margin of 8.27% compared to DocuSign's net margin of 68.1%. DocuSign's return on equity of 70.42% beat Synopsys's return on equity of 30.71%.

DocuSign has a consensus price target of --, signalling upside risk potential of 1.13%. On the other hand Synopsys has an analysts' consensus of $637.78 which suggests that it could grow by 27.52%. Given that Synopsys has higher upside potential than DocuSign, analysts believe Synopsys is more attractive than DocuSign.

DocuSign has a beta of 0.920, which suggesting that the stock is 8.009% less volatile than S&P 500. In comparison Synopsys has a beta of 1.083, suggesting its more volatile than the S&P 500 by 8.289%.

DocuSign has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Synopsys offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DocuSign pays -- of its earnings as a dividend. Synopsys pays out -- of its earnings as a dividend.

DocuSign quarterly revenues are $754.8M, which are smaller than Synopsys quarterly revenues of $1.6B. DocuSign's net income of $62.4M is lower than Synopsys's net income of $1.1B. Notably, DocuSign's price-to-earnings ratio is 19.56x while Synopsys's PE ratio is 34.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DocuSign is 6.82x versus 12.44x for Synopsys. Usually stocks with elevated PS ratios are considered overvalued.